Crinetics Historical Balance Sheet

CRNX Stock

USD 37.35 0.87 2.38%

Trend analysis of Crinetics Pharmaceuticals balance sheet accounts such as Short Long Term Debt Total of 62.5 M, Other Current Liabilities of 37.6 M or Total Current Liabilities of 53.1 M provides information on Crinetics Pharmaceuticals' total assets, liabilities, and equity, which is the actual value of Crinetics Pharmaceuticals to its prevalent stockholders. By breaking down trends over time using Crinetics Pharmaceuticals balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Crinetics Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Crinetics Pharmaceuticals is a good buy for the upcoming year.

Crinetics Pharmaceuticals Inventory

9.75 Million

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Crinetics Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy Crinetics Stock please use our How to Invest in Crinetics Pharmaceuticals guide.

About Crinetics Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Crinetics Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Crinetics Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Crinetics Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Crinetics currently owns. An asset can also be divided into two categories, current and non-current.

Crinetics Pharmaceuticals Balance Sheet Chart

At this time, Crinetics Pharmaceuticals' Non Currrent Assets Other are fairly stable compared to the past year. Cash And Short Term Investments is likely to rise to about 674.5 M in 2025, whereas Net Debt is likely to drop (3 M) in 2025.

Total Assets Short Long Term Debt Total Other Current Liab Total Current Liabilities

Add Fundamental

Total Assets

Total assets refers to the total amount of Crinetics Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Crinetics Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Crinetics Pharmaceuticals balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Crinetics Pharmaceuticals are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most accounts from Crinetics Pharmaceuticals' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Crinetics Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Crinetics Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy Crinetics Stock please use our How to Invest in Crinetics Pharmaceuticals guide.At this time, Crinetics Pharmaceuticals' Non Currrent Assets Other are fairly stable compared to the past year. Cash And Short Term Investments is likely to rise to about 674.5 M in 2025, whereas Net Debt is likely to drop (3 M) in 2025.

	2022	2023	2024	2025 (projected)
Short and Long Term Debt Total	2.0M	51.7M	59.5M	62.5M
Total Assets	352.2M	635.4M	730.7M	767.2M

Short Long Term Debt Total Total Assets

Crinetics Pharmaceuticals balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Long Term Debt Total	Non Current Liabilities Total	Capital Surpluse	Inventory	Other Current Assets	Other Stockholder Equity
Total Assets		0.92	0.99	0.99	0.67	0.9	0.93	0.93	-0.04	-0.97	0.81	0.48	0.94	0.94	0.05	-0.73	1.0	0.97	0.87	0.86	-0.73	0.72	0.81	0.89	0.74	-0.91
Short Long Term Debt Total	0.92		0.94	0.93	0.9	0.84	0.72	1.0	0.25	-0.86	0.63	0.22	1.0	0.99	-0.21	-0.79	0.91	0.99	0.68	0.71	-0.79	0.91	0.6	0.74	0.45	-0.7
Other Current Liab	0.99	0.94		1.0	0.71	0.92	0.9	0.95	0.05	-0.97	0.78	0.4	0.96	0.95	0.02	-0.74	0.99	0.98	0.84	0.85	-0.74	0.77	0.76	0.89	0.7	-0.89
Total Current Liabilities	0.99	0.93	1.0		0.69	0.93	0.9	0.95	0.07	-0.98	0.81	0.38	0.95	0.93	0.05	-0.74	0.99	0.97	0.85	0.86	-0.74	0.76	0.77	0.88	0.72	-0.9
Total Stockholder Equity	0.67	0.9	0.71	0.69		0.61	0.38	0.89	0.48	-0.59	0.3	-0.05	0.88	0.87	-0.51	-0.72	0.65	0.83	0.33	0.4	-0.72	0.94	0.26	0.47	0.03	-0.34
Other Liab	0.9	0.84	0.92	0.93	0.61		0.82	0.85	0.25	-0.9	0.75	0.15	0.86	0.84	0.05	-0.67	0.9	0.88	0.69	0.78	-0.67	0.69	0.7	0.81	0.64	-0.82
Net Tangible Assets	0.93	0.72	0.9	0.9	0.38	0.82		0.75	-0.32	-0.92	0.86	0.67	0.76	0.77	0.3	-0.56	0.95	0.82	0.93	0.87	-0.56	0.43	0.92	0.86	0.9	-0.97
Property Plant And Equipment Net	0.93	1.0	0.95	0.95	0.89	0.85	0.75		0.23	-0.88	0.66	0.24	1.0	0.99	-0.18	-0.79	0.92	0.99	0.7	0.73	-0.79	0.89	0.62	0.76	0.48	-0.72
Net Debt	-0.04	0.25	0.05	0.07	0.48	0.25	-0.32	0.23		0.02	-0.12	-0.89	0.22	0.14	-0.43	-0.21	-0.07	0.15	-0.33	-0.13	-0.21	0.5	-0.36	-0.13	-0.41	0.27
Retained Earnings	-0.97	-0.86	-0.97	-0.98	-0.59	-0.9	-0.92	-0.88	0.02		-0.86	-0.43	-0.89	-0.87	-0.14	0.59	-0.97	-0.92	-0.89	-0.93	0.59	-0.68	-0.77	-0.91	-0.81	0.95
Accounts Payable	0.81	0.63	0.78	0.81	0.3	0.75	0.86	0.66	-0.12	-0.86		0.42	0.67	0.62	0.37	-0.34	0.81	0.72	0.89	0.93	-0.34	0.36	0.85	0.7	0.91	-0.9
Cash	0.48	0.22	0.4	0.38	-0.05	0.15	0.67	0.24	-0.89	-0.43	0.42		0.25	0.33	0.33	-0.17	0.5	0.32	0.67	0.47	-0.17	-0.06	0.64	0.49	0.63	-0.6
Non Current Assets Total	0.94	1.0	0.96	0.95	0.88	0.86	0.76	1.0	0.22	-0.89	0.67	0.25		0.99	-0.17	-0.79	0.93	0.99	0.71	0.74	-0.79	0.89	0.63	0.77	0.5	-0.74
Non Currrent Assets Other	0.94	0.99	0.95	0.93	0.87	0.84	0.77	0.99	0.14	-0.87	0.62	0.33	0.99		-0.23	-0.78	0.93	0.98	0.68	0.71	-0.78	0.86	0.64	0.78	0.47	-0.73
Other Assets	0.05	-0.21	0.02	0.05	-0.51	0.05	0.3	-0.18	-0.43	-0.14	0.37	0.33	-0.17	-0.23		0.18	0.08	-0.09	0.45	0.26	0.18	-0.45	0.45	-0.04	0.52	-0.33
Long Term Debt	-0.73	-0.79	-0.74	-0.74	-0.72	-0.67	-0.56	-0.79	-0.21	0.59	-0.34	-0.17	-0.79	-0.78	0.18		-0.72	-0.78	-0.53	-0.36	1.0	-0.75	-0.45	-0.6	-0.27	0.46
Cash And Short Term Investments	1.0	0.91	0.99	0.99	0.65	0.9	0.95	0.92	-0.07	-0.97	0.81	0.5	0.93	0.93	0.08	-0.72		0.96	0.88	0.87	-0.72	0.7	0.82	0.89	0.76	-0.92
Net Receivables	0.97	0.99	0.98	0.97	0.83	0.88	0.82	0.99	0.15	-0.92	0.72	0.32	0.99	0.98	-0.09	-0.78	0.96		0.77	0.78	-0.78	0.85	0.7	0.8	0.57	-0.8
Common Stock Total Equity	0.87	0.68	0.84	0.85	0.33	0.69	0.93	0.7	-0.33	-0.89	0.89	0.67	0.71	0.68	0.45	-0.53	0.88	0.77		0.87	-0.53	0.4	0.88	0.78	0.91	-0.94
Common Stock Shares Outstanding	0.86	0.71	0.85	0.86	0.4	0.78	0.87	0.73	-0.13	-0.93	0.93	0.47	0.74	0.71	0.26	-0.36	0.87	0.78	0.87		-0.36	0.51	0.74	0.84	0.88	-0.93
Long Term Debt Total	-0.73	-0.79	-0.74	-0.74	-0.72	-0.67	-0.56	-0.79	-0.21	0.59	-0.34	-0.17	-0.79	-0.78	0.18	1.0	-0.72	-0.78	-0.53	-0.36		-0.75	-0.45	-0.6	-0.27	0.46
Non Current Liabilities Total	0.72	0.91	0.77	0.76	0.94	0.69	0.43	0.89	0.5	-0.68	0.36	-0.06	0.89	0.86	-0.45	-0.75	0.7	0.85	0.4	0.51	-0.75		0.23	0.63	0.16	-0.44
Capital Surpluse	0.81	0.6	0.76	0.77	0.26	0.7	0.92	0.62	-0.36	-0.77	0.85	0.64	0.63	0.64	0.45	-0.45	0.82	0.7	0.88	0.74	-0.45	0.23		0.6	0.84	-0.86
Inventory	0.89	0.74	0.89	0.88	0.47	0.81	0.86	0.76	-0.13	-0.91	0.7	0.49	0.77	0.78	-0.04	-0.6	0.89	0.8	0.78	0.84	-0.6	0.63	0.6		0.76	-0.89
Other Current Assets	0.74	0.45	0.7	0.72	0.03	0.64	0.9	0.48	-0.41	-0.81	0.91	0.63	0.5	0.47	0.52	-0.27	0.76	0.57	0.91	0.88	-0.27	0.16	0.84	0.76		-0.93
Other Stockholder Equity	-0.91	-0.7	-0.89	-0.9	-0.34	-0.82	-0.97	-0.72	0.27	0.95	-0.9	-0.6	-0.74	-0.73	-0.33	0.46	-0.92	-0.8	-0.94	-0.93	0.46	-0.44	-0.86	-0.89	-0.93

Click cells to compare fundamentals

Crinetics Pharmaceuticals Account Relationship Matchups

Crinetics Pharmaceuticals balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	183.4M	351.0M	352.2M	635.4M	730.7M	767.2M
Short Long Term Debt Total	4.0M	3.1M	2.0M	51.7M	59.5M	62.5M
Other Current Liab	7.0M	12.6M	17.5M	31.2M	35.8M	37.6M
Total Current Liabilities	10.5M	16.0M	27.7M	43.9M	50.5M	53.1M
Total Stockholder Equity	(167.6M)	(275.3M)	(439.2M)	539.1M	620.0M	651.0M
Net Tangible Assets	117.1M	168.9M	331.9M	316.3M	363.8M	382.0M
Property Plant And Equipment Net	5.4M	4.7M	5.0M	57.4M	66.0M	69.3M
Net Debt	(89.1M)	(197.6M)	(30.6M)	(3.2M)	(2.9M)	(3.0M)
Retained Earnings	(167.6M)	(275.3M)	(439.2M)	(653.7M)	(588.3M)	(558.9M)
Accounts Payable	3.5M	3.4M	6.9M	6.5M	7.5M	3.9M
Cash	93.1M	200.7M	32.7M	54.9M	63.1M	67.8M
Non Current Assets Total	6.0M	6.3M	7.0M	61.2M	70.4M	73.9M
Non Currrent Assets Other	40K	568K	37K	2M	2.3M	2.4M
Other Assets	2.8M	568K	2.0M	1.0	1.15	1.09
Cash And Short Term Investments	170.9M	333.7M	334.4M	558.6M	642.3M	674.5M
Net Receivables	1.8M	2.0M	2.4M	9.4M	10.8M	11.3M
Common Stock Shares Outstanding	30.4M	38.4M	52.0M	58.1M	66.8M	33.4M
Liabilities And Stockholders Equity	(153.1M)	(256.2M)	(403.3M)	635.4M	730.7M	767.2M
Non Current Liabilities Total	4.0M	3.1M	8.1M	52.3M	60.2M	63.2M
Other Current Assets	4.8M	8.1M	10.8M	6.2M	7.2M	5.0M
Other Stockholder Equity	(210.9M)	(336.5M)	(607.2M)	(755.5M)	(680.0M)	(646.0M)
Total Liab	14.5M	19.1M	35.8M	96.2M	110.7M	116.2M
Property Plant And Equipment Gross	3.2M	8.2M	9.1M	62.5M	71.9M	75.5M
Total Current Assets	177.5M	344.7M	345.2M	574.2M	660.3M	693.3M
Accumulated Other Comprehensive Income	25K	(382K)	(3.9M)	977K	879.3K	923.3K
Non Current Liabilities Other	202K	4.8M	4.0M	2K	2.3K	2.2K
Short Term Debt	835K	939K	1.1M	4.2M	4.8M	5.0M
Common Stock	336.5M	607.6M	759.4M	1.2B	1.4B	1.4B
Property Plant Equipment	6.5M	5.4M	4.7M	5.0M	5.7M	4.2M
Net Invested Capital	168.9M	331.9M	316.3M	539.1M	620.0M	651.0M
Net Working Capital	167.0M	328.7M	317.5M	530.2M	609.7M	640.2M
Short Term Investments	77.8M	133.0M	301.8M	503.7M	579.2M	608.2M
Capital Stock	336.5M	607.6M	759.4M	1.2B	1.4B	1.4B
Current Deferred Revenue	(835K)	(939K)	2.2M	2.1M	2.4M	2.5M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

BTC	Bitcoin
TRX	TRON
BNB	Binance Coin

Additional Tools for Crinetics Stock Analysis

When running Crinetics Pharmaceuticals' price analysis, check to measure Crinetics Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Crinetics Pharmaceuticals is operating at the current time. Most of Crinetics Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Crinetics Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Crinetics Pharmaceuticals' price. Additionally, you may evaluate how the addition of Crinetics Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Crinetics Historical Balance Sheet

Crinetics Pharmaceuticals Inventory

9.75 Million

About Crinetics Balance Sheet Analysis

Crinetics Pharmaceuticals Balance Sheet Chart

Total Assets

Total Current Liabilities

Crinetics Pharmaceuticals balance sheet Correlations

Crinetics Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Crinetics Pharmaceuticals balance sheet Accounts

Also Currently Popular

Additional Tools for Crinetics Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Property Plant And Equipment Net	+ 1.0	Short Long Term Debt Total
Non Current Assets Total	+ 1.0	Short Long Term Debt Total
Total Current Liabilities	+ 1.0	Other Current Liab
Non Current Assets Total	+ 1.0	Property Plant And Equipment Net
Long Term Debt Total	+ 1.0	Long Term Debt

Retained Earnings	- 0.98	Total Current Liabilities
Cash And Short Term Investments	- 0.97	Retained Earnings
Other Stockholder Equity	- 0.97	Net Tangible Assets
Retained Earnings	- 0.97	Other Current Liab
Retained Earnings	- 0.97	Total Assets
Other Stockholder Equity	- 0.94	Common Stock Total Equity